Dawn Smiley-Byrd, MD
Endocrinology, Diabetes & Metabolism · Taylorsville, GANPI 1134238827
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $294,403 of the $385,184 with a category attached, or 76.4%. Novo Nordisk accounts for 71.2% of it on its own, with 40 other manufacturers making up the rest. Reporting peaked in 2019 at $103,465 and has fallen 62.9% since, to $38,414 in 2025. Among endocrinology, diabetes & metabolism clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 720 payments — averaging $534.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$274K
- Merck$43K
- Bayer$35K
- Sanofi-aventis U.S. LLC$21K
- Corcept Therapeutics$3K
- Eli Lilly$2K
- plus $7K from 35 others
What the payments were for
- Consulting fees$33,9059%
- Speaking & faculty fees$294,40376%
- Travel & lodging$37,93510%
- Food & beverage$18,6785%
- Education$2630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$78,024
- RYBELSUS$76,955
- Ozempic$47,014
- Saxenda$42,234
- STEGLATRO$31,561
- Kerendia$29,700
- SOLIQUA 100/33$11,439
- Tresiba$9,095
- Victoza$7,849
- TOUJEO$5,444
- STEGLUJAN$4,130
- DISEASE STATE$3,713
- Xultophy 100/3.6$3,223
- Non-Covered$3,200
- Korlym$2,443
- MINIMED 770G$810
- INPEN SMART INSULIN DELIVERY SYSTEM$131
- FARXIGA$125
- AFREZZA$118
- Repatha$108
How this compares
$385,184 in reported general payments places this provider in the 95th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 112 | $169,951 |
| OzempicSemaglutide | 121 | $166,869 |
| TrulicityDulaglutide | 45 | $51,095 |
| JardianceEmpagliflozin | 50 | $47,848 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $35,822 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 29 | $23,348 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $20,280 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $14,347 |
| FarxigaDapagliflozin Propanediol | 14 | $14,000 |
| JanuviaSitagliptin Phosphate | 15 | $13,931 |
| Novolog FlexpenInsulin Aspart | 41 | $11,271 |
| Humalog Kwikpen U-100Insulin Lispro | 32 | $10,705 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $8,948 |
| SynthroidLevothyroxine Sodium | 88 | $7,607 |
| HumalogInsulin Lispro | 13 | $5,159 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $592 | $227,064183 claims |
| Novo NordiskOzempic, Novolog | $274,170 | $171,330135 claims |
| Boehringer IngelheimJardiance | $250 | $47,84850 claims |
| AstraZenecaFarxiga | $267 | $14,00014 claims |
| MerckJanuvia | $42,742 | $13,93115 claims |
| AbbVieSynthroid | $39 | $7,60788 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $80 | $1,162128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Taylorsville
- Maryann MugoTaylorsville$13K
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Adeniyi OdugbesanLawrenceville$636K
- Miguel MunozMarietta$476K
- Jason BernerJasper$457K
- Barry JohnsMacon$335K
- Jonathan OwnbyAtlanta$291K
- Ismary DecastroSavannah$169K
- Naland ShenoySnellville$139K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.